Agios Pharmaceuticals, Inc. $AGIO Shares Bought by Russell Investments Group Ltd.

Russell Investments Group Ltd. lifted its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 207.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 8,558 shares of the biopharmaceutical company’s stock after acquiring an additional 5,776 shares during the period. Russell Investments Group Ltd.’s holdings in Agios Pharmaceuticals were worth $251,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in the stock. GF Fund Management CO. LTD. bought a new stake in shares of Agios Pharmaceuticals in the 4th quarter worth approximately $39,000. CWM LLC raised its holdings in shares of Agios Pharmaceuticals by 150.2% in the 1st quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 996 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Agios Pharmaceuticals by 16.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 3,582 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 499 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Agios Pharmaceuticals by 9,296.6% in the 1st quarter. GAMMA Investing LLC now owns 8,175 shares of the biopharmaceutical company’s stock worth $240,000 after purchasing an additional 8,088 shares in the last quarter. Finally, Commerce Bank bought a new stake in shares of Agios Pharmaceuticals in the 1st quarter worth approximately $240,000.

Insider Activity

In related news, insider James William Burns sold 2,799 shares of the business’s stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $33.54, for a total transaction of $93,878.46. Following the transaction, the insider directly owned 28,650 shares of the company’s stock, valued at approximately $960,921. The trade was a 8.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Brian Goff sold 18,700 shares of the business’s stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $33.54, for a total transaction of $627,198.00. Following the transaction, the chief executive officer directly owned 105,401 shares in the company, valued at $3,535,149.54. The trade was a 15.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 57,448 shares of company stock valued at $2,026,141 in the last three months. 4.93% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. Bank of America dropped their target price on shares of Agios Pharmaceuticals from $52.00 to $51.00 and set a “buy” rating on the stock in a report on Tuesday, July 22nd. Wall Street Zen downgraded shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, May 19th. Finally, Scotiabank dropped their target price on shares of Agios Pharmaceuticals from $71.00 to $65.00 and set a “sector outperform” rating on the stock in a report on Monday, July 28th. Six investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, Agios Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $56.33.

Agios Pharmaceuticals Price Performance

AGIO stock opened at $37.71 on Tuesday. Agios Pharmaceuticals, Inc. has a 52-week low of $23.42 and a 52-week high of $62.58. The company’s 50 day simple moving average is $37.21 and its 200-day simple moving average is $33.08. The firm has a market capitalization of $2.19 billion, a P/E ratio of 3.43 and a beta of 0.87.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.19). Agios Pharmaceuticals had a net margin of 1,590.42% and a negative return on equity of 3.49%. The firm had revenue of $12.50 million for the quarter, compared to analyst estimates of $9.46 million. Sell-side analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.